Esta web utiliza cookies técnicas, de personalización y análisis, propias y de terceros,
para facilitarle la navegación y analizar estadísticas del uso de la web.
Si continúa navegando, consideramos que acepta su uso
5% de descuento en todos los libros solicitados por la web
International experts present innovative therapeutic strategies to treat cancer patients and prevent disease progression
Extracellular Targeting of Cell Signaling in Cancer highlights innovative therapeutic strategies to treat cancer metastasis and prevent tumor progression. Currently, there are no drugs available to treat or prevent metastatic cancer other than non-selective, toxic chemotherapy. With contributions from an international panel of experts in the field, the book integrates diverse aspects of biochemistry, molecular biology, protein engineering, proteomics, cell biology, pharmacology, biophysics, structural biology, medicinal chemistry and drug development.
A large class of proteins called kinases are enzymes required by cancer cells to grow, proliferate, and survive apoptosis (death) by the immune system. Two important kinases are MET and RON which are receptor tyrosine kinases (RTKs) that initiate cell signaling pathways outside the cell surface in response to extracellular ligands (growth factors.) Both kinases are oncogenes which are required by cancer cells to migrate away from the primary tumor, invade surrounding tissue and metastasize. MET and RON reside on both cancer cells and the support cells surrounding the tumor, called the microenvironment. MET and RON are activated by their particular ligands, the growth factors HGF and MSP, respectively. Blocking MET and RON kinase activation and downstream signaling is a promising therapeutic strategy for preventing tumor progression and metastasis. Written for cancer physicians and biologists as well as drug discovery and development teams in both industry and academia, this is the first book of its kind which explores novel approaches to inhibit MET and RON kinases other than traditional small molecule kinase inhibitors. These new strategies target key tumorigenic processes on the outside of the cell, such as growth factor activation by proteases. These unique strategies have promising potential as an improved alternative to kinase inhibitors, chemotherapy, or radiation treatment.
About the Author Dr. James W. Janetka is an Associate Professor at Washington University School of Medicine, and has over 20 years of medicinal chemistry and drug discovery experience within both industry and academia. He has published 50 peer-reviewed manuscripts and holds 20 US patents in oncology and infectious disease.
Roseann Benson is a chemical engineer turned scientific writer and editor. As a consultant for Harvard and Washington University Medical Schools, she has edited and contributed to manuscripts and books that have been published by Wiley, CUP, Nature, and Science.
TABLE OF CONTENTS Ch 1 - Discovery and function of the HGF/MET and the MSP/RON kinase signaling pathways in cancer Silvia Benvenuti, Melissa Milan, and Paolo Comoglio; Candiolo Cancer Institute, Italy
Ch 2 - The role of HGF/MET and MSP/RON signaling in tumor progression and resistance to anticancer therapy Lidija Klampfer; ProteXase Therapeutics, Inc., USA Ben Yaw Owusu; University of Alabama at Birmingham School of Medicine, USA
Ch 3 - HGF Activator (HGFA) and its inhibitors HAI-1 and HAI-2: Key players in tissue repair and cancer Hiroaki Kataoka and Takeshi Shimomura; University of Miyazaki, Japan
Ch 4 - Physiological Functions and Role of Matriptase in Cancer Thomas E. Hyland, Karin List, and Fausto A. Varela; Wayne State University, USA
Ch 5 - The cell-surface, transmembrane serine protease Hepsin: discovery, function and role in cancer Denis Belitskin, Juha Klefström, Shishir Pant, and Topi Tervonen; University of Helsinki, Finland
Ch 6 - Targeting HGF with antibodies as an anticancer therapeutic strategy Donald Bottaro, Dinuka M De Silva, and Arpita Roy; National Cancer Institute, USA
Ch 7 - MET and RON Receptor Tyrosine Kinases as Therapeutic Antibody Targets for Cancer Ling Liu, Mark Wortinger, Jonathan Tetreault, and Nick Loizos; Eli Lilly, USA
Ch 8 - Inhibitory antibodies of the proteases HGFA, matriptase, and hepsin Daniel Kirchoffer, Robert Lazarus, and Charles Eigenbrot; Genentech, USA
Ch 9 - Inhibitors of the growth-factor activating proteases matriptase, hepsin and HGFA: Strategies for rational drug design and optimization Robert Galemmo; ProteXase Therapeutics, Inc., USA, James Janetka; Washington University, USA
Ch 10 - Cyclic peptide serine protease inhibitors based on the natural product SFTI-1 Ashley Buckle, David E. Hoke, Olga Ilyichova, and Blake T. Riley; Monash University, Australia, Jonathan M. Harris; Queensland University of Technology, Australia
Ch 11 - Screening combinatorial peptide libraries in protease inhibitor drug discovery Paulina Kasperkiewicz and Marcin Poreba; Sanford Burnham Prebys Medical Discovery Institute, USA, Marcin Drag and Wioletta Rut; Wroclaw University of Technology, Poland
Ch 12 - Chemical probes targeting proteases for imaging and diagnostics in cancer Pedro Gonçalves and Steven Verhelst; University of Leuven, Belgium
Ch 13 - Cancer Diagnostics of protease activity and metastasis John Beard and Timothy OBrien; Stage I Diagnostics, Inc., USA
Ch 14 - Roles of pericellular proteases in tumor angiogenesis: therapeutic implications Janice Kraniak, Raymond R. Mattingly, and Bonnie Sloane; Wayne State University School, USA